Clinical Guidelines Alert January 2024 Banner
FDA Drug Approvals January 2024 Banner
  • Gammagard (Takeda) Expanded Indication¬†
    • To improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
  • Dupixent (Sanofi / Regeneron) Expanded Indication
    • Treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
  • Zynrelef (Heron Therapeutics) Expanded Indication
    • To expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.
  • Balversa (Janssen)
    • For adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy.
  • HyQvia (Takeda) New Formulation
    • As maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
  • Casgevy (Vertex) New Indication
    • Treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older.
  • Keytruda (Merck) New Indication
    • For patients with FIGO 2014 Stage III-IVA cervical cancer.
  • Zelsuvmi (Ligand Pharmaceuticals)¬†
    • Treatment of molluscum contagiosum (MC) in adults and children aged 1 year or older.

Copyright © 2024 Guideline Central, All rights reserved.